Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/21751
Title: Variation in the use of single- versus multi-fractions palliative radiotherapy for bone metastases in Australia.
Authors: Ong, Wee Loon;Foroudi, Farshad;Milne, Roger L;Millar, Jeremy L
Affiliation: Central Clinical School, Monash University, Australia
Precision Medicine, School of Clinical Sciences, Monash Health, Monash University, Australia
Alfred Health Radiation Oncology Services, Australia
Department of Radiation Oncology, Austin Health, Olivia Newton-John Cancer Wellness and Research Centre, Heidelberg, Victoria, Australia
School of Clinical Medicine, University of Cambridge, UK; Department of Epidemiology and Preventive Medicine, Monash University, Australia
Health and Biomedical Informatics Centre, The University of Melbourne, Australia
Cancer Epidemiology Division, Cancer Council Victoria, Australia
Centre for Epidemiology and Biostatistics, School of Population and Global Health, University of Melbourne, Australia
Issue Date: 7-Sep-2019
EDate: 2019-09-07
Citation: International journal of radiation oncology, biology, physics 2019; online first: 7 September
Abstract: To evaluate the use of single-fraction palliative radiotherapy (SFRT) for the management of bone metastases (BM) in Victoria, Australia METHODS AND MATERIALS: This is a population-based cohort of cancer patients who received RT for BM between 2012 and 2017 as captured in the Victorian Radiotherapy Minimum Data Set (VRMDS). The primary outcome was proportion of SFRT use. The Cochrane-Armitage test for trend was used to evaluate changes in practice over time. Multivariable logistic regression was used to assess factors associated with SFRT use. Of the 18,158 courses of RT for BM delivered in a total of 10,956 patients, 17% were SFRT. There was no significant change in SFRT use over time, from 18% in 2012 to 19% in 2017 (P=0.07). SFRT was less commonly given to skull (4%) and spine (14%), compared to shoulder (37%) and ribs (53%). Patients with lung cancer (21%) were most likely to receive SFRT, followed by those with prostate cancers (18%) and gastrointestinal cancers (16%). Patients from regional/remote areas were more likely to have SFRT compared to those in major cities (22% vs. 16%, P<0.001). Patients treated in public institutions were more likely to have SFRT compared to those treated in private institutions (22% vs. 10%, P<0.001). In multivariable analyses, increasing age, lung cancer, living in regional/remote areas, and being treated in public institutions were factors independently associated with increased likelihood of receiving SFRT. SFRT appears under-utilized for BM in Australia over time, with variation in practice by patient, tumor, geographical and institutional provider factors.
URI: http://ahro.austin.org.au/austinjspui/handle/1/21751
DOI: 10.1016/j.ijrobp.2019.08.061
ORCID: 0000-0001-6657-7193
0000-0001-8387-0965
PubMed URL: 31505246
Type: Journal Article
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.